89bio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Public

  • Employees
  • 93

Employees

  • Stock Symbol
  • ETNB

Stock Symbol

  • Share Price
  • $10.07
  • (As of Friday Closing)

89bio General Information

Description

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

Contact Information

Website
www.89bio.com
Formerly Known As
89Bio Ltd.
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 655 Montgomery Street
  • Suite 1500
  • San Francisco, CA 94111
  • United States
+1 (415)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
LOHAS & Wellness, Life Sciences
Corporate Office
  • 655 Montgomery Street
  • Suite 1500
  • San Francisco, CA 94111
  • United States
+1 (415)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

89bio Stock Performance

As of 20-Jun-2025, 89bio’s stock price is $10.07. Its current market cap is $1.47B with 146M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$10.07 $10.00 $4.16 - $11.84 $1.47B 146M 2.23M -$3.38

89bio Financials Summary

As of 31-Mar-2025, 89bio has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Mar-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 658,899 533,287 617,674 419,097
Revenue 0 0 0 0
EBITDA (403,249) (384,618) (151,154) (102,184)
Net Income (386,673) (367,079) (142,189) (102,026)
Total Assets 685,031 478,685 596,269 196,824
Total Debt 37,579 37,549 27,108 20,546
Public Fundamental Data provided by Morningstar, Inc. disclaimer

89bio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore 89bio‘s full profile, request access.

Request a free trial

89bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercializa
Drug Discovery
San Francisco, CA
93 As of 2024

South San Francisco, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

89bio Competitors (29)

One of 89bio’s 29 competitors is Akero Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Akero Therapeutics Formerly VC-backed South San Francisco, CA
Astria Therapeutics Formerly VC-backed Boston, MA
Altimmune Corporate Backed or Acquired Gaithersburg, MD
Galectin Therapeutics Corporation Norcross, GA
aTyr Pharma Formerly VC-backed San Diego, CA
You’re viewing 5 of 29 competitors. Get the full list »

89bio Patents

  • 83

    Total Documents Applications and Grants

  • Total Patents Families

  • 55

    Granted

  • 23

    Pending

  • Expiring in next 12 mo

89bio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023329349-A1 Methods of treatment of nash using mutant fgf-21 peptide conjugates Pending 24-Aug-2022
US-20230414768-A1 Compositions and methods of treatment for severe hypertriglyceridemia Active 24-Jun-2022
US-12036284-B2 Compositions and methods of treatment for severe hypertriglyceridemia Active 24-Jun-2022
AU-2023287799-A1 Compositions and methods of treatment for severe hypertriglyceridemia Pending 24-Jun-2022
EP-4543479-A1 Compositions and methods of treatment for severe hypertriglyceridemia Pending 24-Jun-2022 A61K47/549
To view 89bio’s complete patent history, request access »

89bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

89bio ESG

Risk Overview

Risk Rating

Updated April, 26, 2025

38.77 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,673

Rank

Percentile

Pharmaceuticals

Industry

of 844

Rank

Percentile

Pharmaceuticals

Subindustry

of 419

Rank

Percentile

To view 89bio’s complete esg history, request access »

89bio FAQs

  • When was 89bio founded?

    89bio was founded in 2018.

  • Where is 89bio headquartered?

    89bio is headquartered in San Francisco, CA.

  • What is the size of 89bio?

    89bio has 93 total employees.

  • What industry is 89bio in?

    89bio’s primary industry is Drug Discovery.

  • Is 89bio a private or public company?

    89bio is a Public company.

  • What is 89bio’s stock symbol?

    The ticker symbol for 89bio is ETNB.

  • What is the current stock price of 89bio?

    As of 20-Jun-2025 the stock price of 89bio is $10.07.

  • What is the current market cap of 89bio?

    The current market capitalization of 89bio is $1.47B.

  • Who are 89bio’s competitors?

    Akero Therapeutics, Astria Therapeutics, Altimmune, Galectin Therapeutics, and aTyr Pharma are some of the 29 competitors of 89bio.

  • What is 89bio’s annual earnings per share (EPS)?

    89bio’s EPS for 12 months was -$3.38.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »